Avanti launches bionano company

Avanti Therapeutics launched a new bionanotechnology company for targeted drug delivery called Chikujee Therapeutics. Chikujee will use Avanti's drug delivery technology to enhance the performance of drugs, specifically anti-cancer drugs. The first drug classes the company will focus on are taxols (Paclitaxel and Docetaxel) and camptothecin for chemotherapy. Chikujee is Avanti's third early-stage company.

- here's the release

Suggested Articles

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.

Scientists at Sanford Burnham Prebys suggested that inhibiting the PPP1R1B protein could be a new strategy for treating pancreatic cancer.